2019
Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial
Cox E, Saramago P, Kelly J, Porta N, Hall E, Tan W, Sculpher M, Soares M. Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial. Clinical Genitourinary Cancer 2019, 18: e418-e442. PMID: 32144049, PMCID: PMC7427321, DOI: 10.1016/j.clgc.2019.12.004.Peer-Reviewed Original ResearchConceptsHealth-related quality of lifeNon-muscle-invasive bladder cancerMuscle-invasive bladder cancerProgression to muscle-invasive bladder cancerQuality of lifePatients' health-related quality of lifePatients' health-related qualityBladder cancerHealth-related qualityEQ-5D-3LGeneralized estimating equationsUK unit costsRandomized controlled trialsHRQoL decrementNon-muscle-invasive bladder cancer patientsHRQoLHealthcare costsHRQOL effectsLimited evidenceControlled trialsEstimating equationsTMN classificationClinical eventsAverage costRecurrence
2018
BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
Kelly J, Tan W, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E, Investigators O. BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology 2018, 75: 593-601. PMID: 30279015, DOI: 10.1016/j.eururo.2018.09.020.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineCarcinoma, Transitional CellCardiovascular DiseasesCelecoxibCyclooxygenase 2 InhibitorsDisease ProgressionDouble-Blind MethodFemaleHumansMaleMiddle AgedMitomycinNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited KingdomUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerHigh-risk non-muscle-invasive bladder cancerRisk of recurrenceIncreased risk of cardiovascular eventsRisk of cardiovascular eventsTime to recurrenceCardiovascular eventsNMIBC patientsBladder cancerStandard treatmentPhase III placebo-controlled trialIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancer patientsIncreased riskPatients treated with celecoxibWeekly mitomycin C instillationsMitomycin C instillationAdjuvant intravesical therapyRecurrence-free rateMedian follow-upPlacebo-controlled trialTransitional cell carcinomaHigh-risk patientsCyclo-oxygenase 2 inhibitorsIntravesical therapyRadiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial
Tan W, Panchal A, Buckley L, Devall A, Loubière L, Pope A, Feneley M, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths T, Page T, Hodgson D, Datta S, Billingham L, Kelly J. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. European Urology 2018, 75: 63-71. PMID: 30274699, DOI: 10.1016/j.eururo.2018.09.005.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerDisease-free survival timeCarcinoma in situBacillus Calmette-GuerinSecond-line therapyTreatment armsComplete responseOpen-labelNo significant differenceBladder cancerCourse of bacillus Calmette-GuerinNon-muscle-invasive bladder cancer patientsBacillus Calmette-Guerin failuresCarcinoma in situ patientsStandard second-line therapyBacillus Calmette-Guerin therapyRecurrence of non-muscle-invasive bladder cancerStandard of care treatmentControlled trialsPapillary bladder lesionsPhase III randomised controlled trialMedian follow-upBladder cancer outcomesSignificant differenceOutcome measures